hervolutiontx.comCrawled Nov 6, 2026
Findings demonstrate HERV-K is required for senescence-associated inflammation in metabolically challenged cells and is reactivated in plasma of subjects living with obesity
Preclinical studies in disease-relevant models demonstrate the ability of HERVolution’s HERV-targeting platform to control weight gain, reverse type 2 diabetes, and lower “inflammaging” biomarkers
Dr. Coleman leads biotech ventures, developing viral-based vaccines and therapeutics from innovation to clinical trials and securing over $120 million in financing.
Jan serves as a CFO and finance executive with expertise in strategic, operational, and analytical management of complex corporate and banking operations.
From her direct interaction with patients through her clinical oncology medical experience, Dr. Gaziel brings unique insights and strategic understanding to the HERVolution team’s efforts to accelerate clinical programs and optimize trial designs to link seamlessly with commercialization strategies.
Dr. Holst founded HERVolution and advanced virus-vectored vaccines by creating the first clinically effective genetic adjuvants, with inventions licensed to GSK.
Dr. Anderson co-developed HERVolution’s adenovirus-encoded virus-like particle vaccines and oversees the company’s platform and process development.
HERVolution Therapeutics is engineering novel immunotherapies that empower the immune system to target HERVs, a class of dark genome antigens impacting cancer as well as metabolic and aging-related diseases.
HERVolution Therapeutics presents data showing **HERV-K** drives metabolic senescence in cells under stress. The findings, shared at the **International Congress on Obesity 2026**, indicate the viral sequence is necessary for inflammation linked to senescence and becomes active in the plasma of obese individuals.
HERVolution Therapeutics shows its HERV-targeting platform can control weight gain, reverse type 2 diabetes, and reduce inflammaging biomarkers in preclinical metabolic disease models. The company also secures an exclusive license agreement with the University of Copenhagen for its technology.
HERVolution Therapeutics adds **Dr. László B. Tankó** to its Scientific Advisory Board to bolster its **cardiometabolic drug development pipeline**. Tankó contributes over **25 years of clinical leadership** from roles at Ferring, Novartis, NIBR, Bayer, and SixPeaks Bio. The appointment aims to refine HERVolution’s clinical strategy for treating cardiometabolic diseases.
HERVolution names **Dr. Tine Gaziel** as Chief Medical Officer to accelerate clinical development of its **dark genome-targeting immune therapy**. Gaziel brings expertise in clinical research and development from roles at **Eli Lilly, Y-mAbs Therapeutics, and Genmab**. The appointment aims to transition the therapy toward clinical trials and potential patient treatment.
Dark Genome Biotech’s HERVolution Therapeutics secures **$11.7 million in Series A funding** to develop immunotherapies targeting **HERV antigens** from the dark genome. The treatments aim to address **cancer, metabolic diseases, and aging-related conditions** by harnessing the immune system. The company specializes in engineering novel approaches to activate immune responses against these previously overlooked genetic elements.
HERVOLUTION Therapeutics names **J. Robert Coleman, PhD, MBA** as CEO to accelerate its novel immunotherapies targeting **dark genome elements** in **cancer, aging, and neurodegenerative diseases**. The biotech company specializes in developing treatments for previously unexplored genetic regions linked to these conditions. Coleman brings extensive biotech leadership experience to drive the company’s pipeline forward.
HERVOLUTION Therapeutics names **Robert S. Langer**, Moderna co-founder and MIT professor, as Chair of its Scientific Advisory Board. The biotech firm develops cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs). Langer’s expertise strengthens HERVOLUTION’s early-stage research in oncology.